1297 related articles for article (PubMed ID: 29644491)
21. Where Do We Stand on the Integration of PARP Inhibitors for the Treatment of Breast Cancer?
Duma N; Gast KC; Choong GM; Leon-Ferre RA; O'Sullivan CC
Curr Oncol Rep; 2018 Jun; 20(8):63. PubMed ID: 29884921
[TBL] [Abstract][Full Text] [Related]
22. The efficacy and safety of PARP inhibitors in mCRPC with HRR mutation in second-line treatment: a systematic review and bayesian network meta-analysis.
Zhu Q; Chen J; Liu H; Zhao J; Xu C; Sun G; Zeng H
BMC Cancer; 2024 Jun; 24(1):706. PubMed ID: 38851712
[TBL] [Abstract][Full Text] [Related]
23. Poly (ADP-ribose) Polymerase Inhibition in Patients with Breast Cancer and BRCA 1 and 2 Mutations.
Jerez Y; Márquez-Rodas I; Aparicio I; Alva M; Martín M; López-Tarruella S
Drugs; 2020 Feb; 80(2):131-146. PubMed ID: 31823331
[TBL] [Abstract][Full Text] [Related]
24. Olaparib tablets for the treatment of germ line BRCA-mutated metastatic breast cancer.
Le D; Gelmon KA
Expert Rev Clin Pharmacol; 2018 Sep; 11(9):833-839. PubMed ID: 30118334
[TBL] [Abstract][Full Text] [Related]
25. Baseline clinical predictors of antitumor response to the PARP inhibitor olaparib in germline BRCA1/2 mutated patients with advanced ovarian cancer.
Rafii S; Gourley C; Kumar R; Geuna E; Ern Ang J; Rye T; Chen LM; Shapira-Frommer R; Friedlander M; Matulonis U; De Greve J; Oza AM; Banerjee S; Molife LR; Gore ME; Kaye SB; Yap TA
Oncotarget; 2017 Jul; 8(29):47154-47160. PubMed ID: 28454085
[TBL] [Abstract][Full Text] [Related]
26. Clinical effectiveness of olaparib monotherapy in germline BRCA-mutated, HER2-negative metastatic breast cancer in a real-world setting: phase IIIb LUCY interim analysis.
Gelmon KA; Fasching PA; Couch FJ; Balmaña J; Delaloge S; Labidi-Galy I; Bennett J; McCutcheon S; Walker G; O'Shaughnessy J;
Eur J Cancer; 2021 Jul; 152():68-77. PubMed ID: 34087573
[TBL] [Abstract][Full Text] [Related]
27. Dissecting PARP inhibitor resistance with functional genomics.
Pettitt SJ; Lord CJ
Curr Opin Genet Dev; 2019 Feb; 54():55-63. PubMed ID: 30954761
[TBL] [Abstract][Full Text] [Related]
28. PARP inhibitors in ovarian cancer: Sensitivity prediction and resistance mechanisms.
Jiang X; Li X; Li W; Bai H; Zhang Z
J Cell Mol Med; 2019 Apr; 23(4):2303-2313. PubMed ID: 30672100
[TBL] [Abstract][Full Text] [Related]
29. PARP inhibitors in older patients with ovarian and breast cancer: Young International Society of Geriatric Oncology review paper.
Liposits G; Loh KP; Soto-Perez-de-Celis E; Dumas L; Battisti NML; Kadambi S; Baldini C; Banerjee S; Lichtman SM
J Geriatr Oncol; 2019 Mar; 10(2):337-345. PubMed ID: 30333088
[TBL] [Abstract][Full Text] [Related]
30. Clinical Application of Poly(ADP-Ribose) Polymerase Inhibitors in High-Grade Serous Ovarian Cancer.
Parkes EE; Kennedy RD
Oncologist; 2016 May; 21(5):586-93. PubMed ID: 27022037
[TBL] [Abstract][Full Text] [Related]
31. Olaparib in germline-mutated metastatic breast cancer: implications of the OlympiAD trial.
Armstrong AC; Clay V
Future Oncol; 2019 Jul; 15(20):2327-2335. PubMed ID: 31304797
[TBL] [Abstract][Full Text] [Related]
32. The evolution of poly(ADP-ribose) polymerase inhibitors in the treatment of breast cancer.
Domchek SM
Clin Adv Hematol Oncol; 2018 May; 16(5):330-332. PubMed ID: 29851928
[No Abstract] [Full Text] [Related]
33. Clinical Use of PARP Inhibitors in BRCA Mutant and Non-BRCA Mutant Breast Cancer.
Lynce F; Robson M
Cancer Treat Res; 2023; 186():91-102. PubMed ID: 37978132
[TBL] [Abstract][Full Text] [Related]
34. Loss of Heterozygosity of
Mizrahi AG; Hamad H; Gugenheim A; Nisman B; Kuznetz A; David IB; Gelfend Y; Cohen S; Zick A; Sheva K; Nechushtan H; Peretz T; Meirovitz A
Anticancer Res; 2022 Nov; 42(11):5257-5263. PubMed ID: 36288893
[TBL] [Abstract][Full Text] [Related]
35. Efficacy of poly (ADP-ribose) polymerase inhibitors monotherapy and the impact to subsequent platinum-based chemotherapy in breast cancer susceptibility genes1/2-mutated ovarian cancer patients with secondary platinum-sensitive relapse.
Ma Y; Liu J; Li N; Bu H; Huang Y; Jin C; Wen H; Feng S; Zhang H; Yang X; Kong B; Wu L; Song K
J Ovarian Res; 2023 Oct; 16(1):209. PubMed ID: 37891662
[TBL] [Abstract][Full Text] [Related]
36. RAD51 foci as a functional biomarker of homologous recombination repair and PARP inhibitor resistance in germline BRCA-mutated breast cancer.
Cruz C; Castroviejo-Bermejo M; Gutiérrez-Enríquez S; Llop-Guevara A; Ibrahim YH; Gris-Oliver A; Bonache S; Morancho B; Bruna A; Rueda OM; Lai Z; Polanska UM; Jones GN; Kristel P; de Bustos L; Guzman M; Rodríguez O; Grueso J; Montalban G; Caratú G; Mancuso F; Fasani R; Jiménez J; Howat WJ; Dougherty B; Vivancos A; Nuciforo P; Serres-Créixams X; Rubio IT; Oaknin A; Cadogan E; Barrett JC; Caldas C; Baselga J; Saura C; Cortés J; Arribas J; Jonkers J; Díez O; O'Connor MJ; Balmaña J; Serra V
Ann Oncol; 2018 May; 29(5):1203-1210. PubMed ID: 29635390
[TBL] [Abstract][Full Text] [Related]
37. PARP inhibitors in breast cancer: Bringing synthetic lethality to the bedside.
Turk AA; Wisinski KB
Cancer; 2018 Jun; 124(12):2498-2506. PubMed ID: 29660759
[TBL] [Abstract][Full Text] [Related]
38. [Abnormalities of DNA repair and gynecological cancers].
Auguste A; Leary A
Bull Cancer; 2017 Nov; 104(11):971-980. PubMed ID: 29054544
[TBL] [Abstract][Full Text] [Related]
39. Olaparib maintenance monotherapy in platinum-sensitive, relapsed ovarian cancer without germline
Poveda AM; Davidson R; Blakeley C; Milner A
Future Oncol; 2019 Nov; 15(32):3651-3663. PubMed ID: 31553234
[TBL] [Abstract][Full Text] [Related]
40. PARP inhibitor resistance and TP53 mutations in patients treated with olaparib for BRCA-mutated cancer: Four case reports.
Collot T; Niogret J; Carnet M; Chevrier S; Humblin E; Favier L; Bengrine-Lefevre L; Desmoulins I; Arnould L; Boidot R
Mol Med Rep; 2021 Jan; 23(1):. PubMed ID: 33236159
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
